Lantheus Medical Imaging to Present Clinical Data on Investigational Cardiac PET Imaging Agents at American Society of Nuclear Cardiology
9/20/2010 11:19:37 AM
N. BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced that seven abstracts related to two of the company’s cardiac Positron Emission Tomography (PET) imaging candidates will be presented at ASNC2010, the 15th Annual Scientific Session of the American Society of Nuclear Cardiology, being held September 23-26, 2010 in Philadelphia. Data being presented include preliminary results from a single site Phase 2 study on flurpiridaz F 18 (formerly known as BMS747158), a myocardial perfusion PET imaging candidate in development to diagnose coronary artery disease, and Phase 1 data on LMI 1195, a novel cardiac neuronal PET imaging candidate. These abstracts will be highlighted in a series of poster presentations at the meeting.